{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T21:34:48Z","timestamp":1715981688437},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1097\/cnd.0000000000000083","type":"journal-article","created":{"date-parts":[[2015,8,22]],"date-time":"2015-08-22T14:35:30Z","timestamp":1440254130000},"page":"1-5","source":"Crossref","is-referenced-by-count":7,"title":["Fludarabine in the Treatment of Refractory Chronic Inflammatory Demyelinating Neuropathies"],"prefix":"10.1097","volume":"17","author":[{"given":"Megan M.","family":"Leitch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas H.","family":"Brannagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-1-20210126","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/ana.410110205","article-title":". Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment.","volume":"11","author":"Dyck","year":"1982","journal-title":"Ann Neurol"},{"key":"R2-1-20210126","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":". Intravenous immune globulin (10 caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial.","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol"},{"key":"R3-1-20210126","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/brain\/119.4.1055","article-title":". Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study.","volume":"119","author":"Hahn","year":"1996","journal-title":"Brain"},{"key":"R4-1-20210126","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1212\/WNL.48.2.321","article-title":"Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy.","volume":"48","author":"Gorson","year":"1997","journal-title":"Neurology"},{"key":"R5-1-20210126","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ana.21577","article-title":". Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy.","volume":"65","author":"Dalakas","year":"2009","journal-title":"Ann Neurol"},{"key":"R7-1-20210126","first-page":"28","article-title":". Fludarabine phosphate: a new active agent in hematologic malignancies.","volume":"31","author":"Keating","year":"1994","journal-title":"Semin Hematol"},{"key":"R8-1-20210126","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF00874436","article-title":"Fludarabine phosphate. A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma.","volume":"12","author":"Rodriguez","year":"1994","journal-title":"Invest New Drugs"},{"key":"R9-1-20210126","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00262-010-0920-3","article-title":". Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia.","volume":"60","author":"Gassner","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"R10-1-20210126","first-page":"326","article-title":"Fludarabine for IgM Antibody-mediated neuropathies.","volume":"36","author":"Sherman","year":"1994","journal-title":"Ann Neurol"},{"key":"R11-1-20210126","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/jnnp.66.5.575","article-title":". Successful treatment of IgM paraproteinaemic neuropathy with fludarabine.","volume":"66","author":"Wilson","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R12-1-20210126","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1529-8027.2011.00343.x","article-title":". Long-term response to rituximab and fludarabine combination in IgM anti-myelin-associated glycoprotein neuropathy.","volume":"16","author":"Gruson","year":"2011","journal-title":"J Peripher Nerv Syst"},{"key":"R13-1-20210126","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jns.2011.12.001","article-title":". Fludarabine may overcome resistance to rituximab in IgM-related neuropathy.","volume":"315","author":"Koya","year":"2012","journal-title":"J Neurol Sci"},{"key":"R14-1-20210126","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1212\/01.wnl.0000247671.58066.21","article-title":". Neurologic and hematologic response to fludarabine treatment in IgM MGUS polyneuropathy.","volume":"67","author":"Niermeijer","year":"2006","journal-title":"Neurology"},{"key":"R15-1-20210126","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/mus.23629","article-title":"Distal acquired demyelinating symmetric polyneuropathy progressing to classic chronic inflammatory demyelinating polyneuropathy and response to fludarabine and cyclophosphamide.","volume":"47","author":"Leitch","year":"2013","journal-title":"Muscle Nerve"},{"key":"R16-1-20210126","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":". IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkins lymphoma.","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"R17-1-20210126","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1212\/WNL.58.12.1856","article-title":". High-dose cyclophosphamide without stem-cell rescue for refractory CIDP.","volume":"58","author":"Brannagan","year":"2002","journal-title":"Neurology"},{"key":"R18-1-20210126","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","article-title":". Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.","volume":"107","author":"Eichhorst","year":"2006","journal-title":"Blood"},{"key":"R19-1-20210126","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2010.89","article-title":". Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy.","volume":"24","author":"Ysebaert","year":"2010","journal-title":"Leukemia"}],"container-title":["Journal of Clinical Neuromuscular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CND.0000000000000083","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T20:25:04Z","timestamp":1621887904000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00131402-201509000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/cnd.0000000000000083","relation":{},"ISSN":["1522-0443"],"issn-type":[{"value":"1522-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}